Pure Global AI
NCT06280079Not yet recruiting

Ultra-high-caloric, Fatty Diet in ALS

Efficacy, Safety, and Tolerability of Ultra-high-caloric, Fatty Diet (UFD) in Amyotrophic Lateral Sclerosis (ALS)
University of UlmClinicalTrials.govdietary supplement
Verified
Study focus
Disease/Condition
Amyotrophic Lateral Sclerosis
Drug/Device/Intervention
Ultra-high-caloric fatty diet
Study type
Interventional
Intervention type
dietary supplement
Sponsor & location
Primary sponsor
University of Ulm
Location
Aachen,Berlin,Bochum,Bonn,Dresden,Erlangen,Essen,Göttingen,Halle,Hannover,Jena,Kassel,Kempten,Leipzig,Lübeck,Mannheim,Munich,Münster,Regensburg,Rostock,Ulm,Wiesbaden,Würzburg, Germany
Timeline & enrollment
Phase
N/A
Start date
May 01, 2024
End date
May 01, 2027
Enrollment
392 participants
Primary outcome

Survival

Summary

This study aims at evaluating efficacy and tolerability of an ultra-high-caloric, fatty diet
 (UFD) compared to placebo in patients with amyotrophic lateral sclerosis (ALS).

ICD-10 classifications
Neuralgic amyotrophyMotor neuron diseaseOther degenerative diseases of the nervous systemOther degenerative disorders of nervous system in diseases classified elsewhereMultiple sclerosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06280079
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06280079 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Ulm and is currently Not yet recruiting. The study focuses on Amyotrophic Lateral Sclerosis. Target enrollment is 392 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.